Press Release

<p><strong>Responsible for Marketing for Newly Created Orthopedics/Urology Business Unit</strong> </p> <table class="newsroom"> <tr> <td valign="top" width="57"><p><b>Contact:</b></p></td> <td width="20" valign="top"></td> <td width="304"> <p>Kelly Laban<br> Kovak-Likly Communications<br> (203)762-8833 x15 or</p> </td> </tr> </table> <p>Pictured: William N. Garbarini, Jr., appointed senior director of marketing for the Orthopedics/Urology Business Unit for Ferring Pharmaceuticals </p> <p>Suffern, NY &ndash; May 11, 2005 &ndash; Ferring Pharmaceuticals Inc. announced that William N. Garbarini, Jr. has been appointed senior director of marketing for its new Orthopedics/Urology Business Unit. In his new role, Garbarini will be responsible for the strategic direction and implementation of marketing programs for products with significant growth potential in these therapeutic areas.</p> <p>&ldquo;Bill excelled in his role as director of marketing for the infertility product line and in his responsibilities for the company&rsquo;s out-license relationships,&rdquo; said Wayne Anderson, president. &ldquo;With his proven track record, we are confident that he will lead the newly created business unit&rsquo;s marketing efforts to great success.&rdquo; </p> <p>In his new capacity, Garbarini is responsible for marketing NUFLEXXA&trade;, an injectable hyaluronic acid for pain from knee osteoarthritis. He will continue to be responsible for the out- license relationships of DDAVP (Aventis) and Pentasa (Shire). Garbarini joined Ferring in 2001 as product director. In 2002, he was promoted to director of marketing for Ferring&rsquo;s infertility products, and was also responsible for the out-license relationships of DDAVP and Pentasa. </p> <p>Prior to joining Ferring, Garbarini was director, client services for Caresoft, Inc. and product manager for the Proventil<sup>&reg;</sup> family of inhaled asthma medications at Schering-Plough Corporation/ Key Pharmaceuticals. </p> <p><strong>About Ferring Pharmaceuticals Inc.</strong><br/> Ferring Pharmaceuticals Inc., part of the Ferring Group, a privately owned, international pharmaceutical company, markets MENOPUR<sup>&reg;</sup> (menotropins for injection, USP), BRAVELLE<sup>&reg;</sup> (urofollitropin for injection, purified), REPRONEX<sup>&reg;</sup> (menotropins for injection, USP) and NOVAREL&trade; (chorionic gonadotropin for injection, USP) in the U.S. to infertility specialists and their patients. Ferring also offers the Q∙CAP&trade;, the first and only needle-free reconstitution device, for use with its fertility treatments. Ferring&rsquo;s line of orthopedic and urology products include NUFLEXXA&trade;, hyaluronic acid for pain from osteoarthritis in the knee and DEGARELIX for prostate cancer (Phase III). Other products include ACTHREL<sup>&reg;</sup> (corticorelin ovine triflutate for injection) for the differential diagnosis of Cushing&rsquo;s syndrome and generic DESMOPRESSIN ACETATE in injectable and rhinal tube forms for the treatment of diabetes insipidus and primary nocturnal enuresis. The Ferring Group specializes in the research, development and commercialization of compounds in general and pediatric endocrinology, urology, gastroenterology, obstetrics/gynecology and infertility. For more information, visit </p> <p># # # </p>